Floatz logo

Eli-002 7P

Colorectal Cancer

Elicio TherapeuticsUNKNOWNPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
59/ 100

Competitive context

713 Active assets in the Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
Orectalip
Sinphar Pharmaceutical Co., Ltd
Phase 4BB
FLUOROURACILUM
UNICANCER
Phase 4BB
LEVOFOLINIC ACID
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Eli-002 7P is also rated in:

pancreatic ductal adenocarcinomaActive
CCC
Indicative · Phase 1/2
49 / 100
View asset →
bile duct cancerActive
CC
Indicative · Phase 1
46 / 100
View asset →
gallbladder carcinomaActive
CC
Indicative · Phase 1
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →